The potential of genotype-guided antiplatelet therapy: promises and challenges

References

• Tantry US, Etherington A, Bliden KP, et al. Antiplatelet therapy: current strategies and future trends. Future Cardiol 2006;2:343–366.
   PubMedGoogle Scholar
• Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother 2005;6:2027–2045.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
   Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation. 2010;121:569–583.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 2009;5:989–1004.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012;125:1276–1287.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–362.
   PubMed Web of Science ®Google Scholar
• FDA Drug SafetyCommunication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm (Accessed on 8-1-2018).
   Google Scholar
• Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010;50:126–142.
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 2010;38:92–99.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol 2010;56:112–126.
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Stein CM, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94:317–323.
   Google Scholar
• Hulot JS, Bura A, Villard E, et al. Cytochrome p450 2c loss-of-functionis a major determinanat of clopidogrel resssponsiveless in healty subjects. Blood. 2006;108:2244–2247.
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–857.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Shuldiner AR, Bliden KP, et al. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J. 2011;161:598–604.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Ohman EM, Jeong YH, Tantry US. Toward a therapeutic window forantiplatelet therapy in the elderly. Eur Heart J. 2012;33:1187–1189.
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, et al; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261–2273.
   Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312–1319.
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF et al.; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320–1328.
   Google Scholar
• Simon T, Verstuyft C, Mary-Krause M et al. French Registry of Acute ST-Elevation and Non –ST Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinates of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–375.
   Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821–1830.
   PubMed Web of Science ®Google Scholar
• Paré G, Mehta SR, Yusuf S, et al. Effects of cyp2c19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704–1714.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, et al. CHARISMA Investigators. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012;33:2143–2150.
   Google Scholar
• Notarangelo FM, Maglietta G, Bevilacqua P, et al. Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial. J Am Coll Cardiol. 2018;71:1869–1877.
   PubMed Web of Science ®Google Scholar
• Price MJ, Murray SS, Angiolillo DJ, et al. GIFT Investigators. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J AmColl Cardiol. 2012;59:1928–1937.
   Google Scholar
• Small DS, Farid NA, Payne CD et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pahrmacoinet 2010;49;777-798.
   Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553–2560.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Kereiakes DJ, Tantry US. Ticagrelor for the treatment of arterial thrombosis. Expert Opin Pharmacother. 2010;11:2251–2259.
   PubMed Web of Science ®Google Scholar
• Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3:556–566.
   PubMed Web of Science ®Google Scholar
• Sánchez-Ramos J, Dávila-Fajardo CL, et al. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent. Int J Cardiol. 2016;225:289–295.
   PubMed Web of Science ®Google Scholar
• Shen DL, Wang B, Bai J, et al. Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population. J Cardiovasc Pharmacol. 2016;67:232–236.
   PubMed Web of Science ®Google Scholar
• Ohman EM. P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes. Presented at: American Heart Association 2017 Scientific Sessions. November 14, 2017. Anaheim, CA.
   Google Scholar
• Cavallari LH, Lee CR, Beitelshees AL, et al. IGNITE Network. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2018;11:181–191.
   Google Scholar
• Gurbel PA. Bedside Testing of CYP2C19 Genotype to Guide Antiplatelet Therapy: Implementation in the Catheterization Laboratory. Presented at 67th American College of Cardiology Scientific Sessions. March12, 2018. Orlando, FL.
   Google Scholar
• Bergmeijer TO, Janssen PW, Schipper JC, et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J. 2014;168:16–22.e1.
   PubMedGoogle Scholar
• Johnson SG, Gruntowicz D, Chua T, Morlock RJ. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention. J Manag Care Spec Pharm. 2015;21:552–557.
   PubMed Web of Science ®Google Scholar
• Kazi DS, Garber AM, Shah RU, et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014;160:221–232.
   PubMed Web of Science ®Google Scholar